UroGen Pharma (URGN) Short Interest Ratio & Short Volume → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free URGN Stock Alerts $14.21 -0.32 (-2.20%) (As of 04/24/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma Short Interest DataCurrent Short Volume4,190,000 sharesPrevious Short Volume4,250,000 sharesChange Vs. Previous Month-1.41%Dollar Volume Sold Short$62.85 millionShort Interest Ratio / Days to Cover12.6Last Record DateMarch 31, 2024Outstanding Shares23,450,000 sharesPercentage of Shares Shorted17.87%Today's Trading Volume97,025 sharesAverage Trading Volume300,547 sharesToday's Volume Vs. Average32% Short Selling UroGen Pharma ? Sign up to receive the latest short interest report for UroGen Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatURGN Short Interest Over TimeURGN Days to Cover Over TimeURGN Percentage of Float Shorted Over Time Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! UroGen Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20244,190,000 shares $62.85 million -1.4%N/A12.6 $15.00 3/15/20244,250,000 shares $61.46 million +8.1%N/A12.4 $14.46 2/29/20243,930,000 shares $72.04 million -2.0%N/A12.7 $18.33 2/15/20244,010,000 shares $75.39 million +23.0%N/A13.2 $18.80 1/31/20243,260,000 shares $51.18 million -3.8%N/A11 $15.70 1/15/20243,390,000 shares $49.46 million -4.5%N/A12.9 $14.59 Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 12/31/20233,550,000 shares $53.25 million +15.6%N/A13.5 $15.00 12/15/20233,070,000 shares $46.05 million +5.1%N/A11.3 $15.00 11/30/20232,920,000 shares $38.51 million +3.2%N/A12.4 $13.19 11/15/20232,830,000 shares $32.77 million +23.6%N/A11.4 $11.58 10/31/20232,290,000 shares $25.67 million +39.6%N/A7.9 $11.21 10/15/20231,640,000 shares $21.48 million +14.7%N/A2.6 $13.10 9/30/20231,430,000 shares $20.03 million +10.9%N/A2.3 $14.01 9/15/20231,290,000 shares $20.52 million -8.5%N/A2.1 $15.91 8/31/20231,410,000 shares $24.65 million -15.1%N/A2.2 $17.48 8/15/20231,660,000 shares $37.12 million +5.7%N/A2.7 $22.36 7/31/20231,570,000 shares $34.01 million +55.5%N/A2.8 $21.66 7/15/20231,010,000 shares $9.28 million +11.1%5.1%4 $9.19 6/30/2023909,100 shares $9.41 million +38.5%4.6%3.8 $10.35 6/15/2023656,300 shares $8.07 million -23.0%3.3%2.7 $12.29 5/31/2023852,100 shares $8.44 million -9.8%4.3%4.6 $9.90 5/15/2023944,700 shares $11.16 million +29.3%4.8%5.4 $11.81 4/30/2023730,500 shares $8.47 million -1.8%3.7%4.3 $11.59 4/15/2023743,700 shares $7.16 million +16.3%3.8%5.8 $9.63 3/31/2023639,500 shares $5.91 million +2.3%3.3%5.6 $9.24 3/15/2023625,300 shares $6.02 million +5.5%3.3%6.3 $9.63 2/28/2023592,900 shares $6.11 million +2.8%3.1%6.7 $10.30 2/15/2023576,700 shares $5.29 million +1.2%3.0%6.4 $9.17 1/31/2023569,700 shares $5.92 million +0.0%3.0%6.6 $10.39 1/15/2023569,600 shares $4.88 million -15.2%2.9%7.7 $8.56 12/30/2022671,700 shares $5.96 million -0.2%3.5%8.9 $8.87 12/15/2022673,000 shares $5.32 million +0.1%3.5%10.2 $7.91 11/30/2022672,600 shares $5.76 million -1.0%3.5%10.3 $8.57 11/15/2022679,700 shares $6.17 million -9.5%3.5%10.5 $9.08 10/31/2022751,100 shares $8.90 million -31.7%3.9%13 $11.85 10/15/20221,100,000 shares $12.65 million -20.3%5.8%19.5 $11.50 9/30/20221,380,000 shares $11.48 million -3.5%7.2%25.6 $8.32 9/15/20221,430,000 shares $13.46 million +1.4%7.5%15 $9.41 8/31/20221,410,000 shares $10.50 million -3.4%7.3%13 $7.45 8/15/20221,460,000 shares $12.64 million -0.7%7.6%10.3 $8.66Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now URGN Short Interest - Frequently Asked Questions What is UroGen Pharma's current short interest? Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 4,190,000 shares of URGN short. Learn More on UroGen Pharma's current short interest. What is a good short interest ratio for UroGen Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. URGN shares currently have a short interest ratio of 13.0. Learn More on UroGen Pharma's short interest ratio. Which institutional investors are shorting UroGen Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of UroGen Pharma: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is UroGen Pharma's short interest increasing or decreasing? UroGen Pharma saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 4,190,000 shares, a decline of 1.4% from the previous total of 4,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does UroGen Pharma's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to UroGen Pharma: Precigen, Inc. (13.66%), Mereo BioPharma Group plc (1.86%), Ventyx Biosciences, Inc. (19.58%), Rani Therapeutics Holdings, Inc. (16.70%), Neoleukin Therapeutics, Inc. (0.35%), ESSA Pharma Inc. (1.81%), Enanta Pharmaceuticals, Inc. (13.94%), Nature's Sunshine Products, Inc. (0.60%), Atai Life Sciences (4.81%), Esperion Therapeutics, Inc. (11.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short UroGen Pharma stock? Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. URGN shares are trading down $0.32 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against UroGen Pharma? A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further. How often is UroGen Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Rani Therapeutics Short Interest Data Mereo BioPharma Group Short Interest Data Precigen Short Interest Data Atai Life Sciences Short Interest Data Amarin Short Interest Data Harrow Health Short Interest Data Atea Pharmaceuticals Short Interest Data Aquestive Therapeutics Short Interest Data Nature's Sunshine Products Short Interest Data Nkarta Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:URGN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society